The average price reduction is 48%, focusing on the focus of the 7th batch of national drug centralized purchase
2022-07-14
The seventh batch of centralized drug procurement organized by the state came to an end in Nanjing, Jiangsu Province on the 12th, and the results of the proposed selection were produced: 60 drugs were included in the procurement, and the average price reduction of 327 products proposed to be selected was 48%. According to the agreed procurement volume, it is estimated that 18.5 billion yuan can be saved annually. This is the first time that the state organized the centralized purchase of drugs in 2022, involving many types of drugs, optimizing the proportion of drugs taken, and adopting "one province, two supplies" have become the focus of this centralized purchase. The coverage of drugs involving 31 treatment categories was further expanded The national drug collection involves 31 treatment categories, including drugs for common and chronic diseases such as hypertension, diabetes, anti infection and digestive tract diseases, as well as drugs for major diseases such as lung cancer, liver cancer, kidney cancer and colon cancer, which benefit the masses widely. "It is worth mentioning that more new drugs have been included in this centralized purchase, which greatly improves the accessibility of drugs." Lu Yun, a professor at the International School of medicine and business, China Pharmaceutical University, said that for example, there are few kinds of drugs available for the treatment of liver cancer, many of which are new drugs with high prices, but renvatinib, which has just passed the patent period, is included in the centralized collection, which can benefit more patients. As a first-line targeted drug for liver cancer, renvatinib capsules decreased from 108 yuan to an average of 18 yuan per capsule, saving 8100 yuan per treatment cycle. In addition, in the field of blood pressure reduction, the controlled-release nifedipine tablets were reduced by 58% and metoprolol sustained-release tablets by 53% for the first time, which significantly reduced the drug burden of patients with hypertension; The antiviral drug oseltamivir was reduced from an average of 4.5 yuan to 1 yuan per tablet. Lu Yun said that among the drugs included in the centralized collection this time, there is also the anti rejection drug mycophenolate mofetil, with emphasis on the monitoring drug edaravone. The drugs included in the centralized collection scope are becoming more and more extensive, reflecting the "should be collected to the end". Optimize the proportion of drug delivery, and make people use drugs more reasonable In the previous centralized purchase of drugs organized by the state, antibiotics, regardless of level, were uniformly reduced by 10% of the agreed purchase volume compared with ordinary varieties. "In the seventh batch of centralized drug purchase organized by the state, the agreed purchase volume of four antibiotics is reduced by another 10% on the basis of other antibiotics, that is, 20% less than that of ordinary varieties." Lu Yun said that further reducing the proportion of special grade antibiotic drugs will play a guiding and normative role in the rational use of drugs in grass-roots medical institutions. Chang Feng, Dean of the school of international pharmaceutical business, China Pharmaceutical University, said that from the optimization of the variety reporting method and the reduction of the proportion of the quantity in the seventh batch of centralized drug purchase, the operation mode of quantity procurement has been further standardized and refined in practice. This will make the implementation of centralized purchase results more operational and more suitable for the actual market use of varieties. According to the relevant person in charge of the national medical insurance administration, the products of 217 enterprises in this centralized purchase were qualified for the proposed selection. The proportion of bidding enterprises was 73%. On average, 5.4 enterprises were selected for each drug variety, and the supply diversification and stability were further enhanced. Up to now, the state has organized the centralized purchase of drugs, covering a total of 294 drugs. According to the price before the centralized purchase, the amount involved accounts for about 35% of the annual purchase amount of chemical drugs and biological drugs of public medical institutions. "One province, two supplies" effectively guarantees clinical medication In order to better ensure the stable supply of drugs under centralized purchase, the mode of "double supply and double guarantee in one province" was introduced for the first time. Chang Feng explained that according to the results of drug selection, if the selected enterprises fail to supply the selected varieties in time and in sufficient quantity or cancel the qualification of the selected varieties, which makes the agreement unable to continue to be performed, the corresponding selected varieties will be supplied by the candidate enterprises in the provinces where they are located. This will provide a double guarantee for the timely, stable and smooth supply of drugs. "This rule also reflects the equivalence of rights and obligations to a certain extent. Alternative enterprises need to supply at the selected price in the supply area, and have the opportunity to obtain more market demand in the province." Chang Feng said that for local medical insurance departments, "one province, two supplies" provides a more secure and direct means to meet the market supply demand, and further reduces the administrative costs of provinces choosing alternative enterprises. "Centralized purchase will achieve win-win results for patients, hospitals, enterprises and other parties." Jiangchangshong, director of the price bidding and Purchasing Department of the National Institute of medical security, Capital Medical University, said that entering a new era of medical price governance, volume procurement and medical insurance negotiation have become two mechanisms for the formation of medical prices, jointly promoting the rationalization of medical prices. It is reported that after the announcement of the results of the proposed election, the official results of the election will be released, which is expected to be implemented in November 2022. (outlook new era)
Edit：Yuanqi Tang Responsible editor：Xiao Yu
Source：
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
